⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862011 | 0.88 | — | — | |
| SCHEMBL65096 | 0.73 | — | — | |
| SCHEMBL1112686 | 0.70 | — | — | |
| SCHEMBL1113117 | 0.70 | — | — | |
| SCHEMBL1541394 | 0.70 | — | — | |
| SCHEMBL1113115 | 0.70 | — | — | |
| SCHEMBL1112682 | 0.70 | — | — | |
| SCHEMBL1541370 | 0.70 | — | — | |
| SCHEMBL1540769 | 0.67 | — | — | |
| SCHEMBL1114039 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4341241-A1 | CONTINUOUS FLOW PROCESS FOR PRODUCTION OF CATIONIC LIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023250427-A2 | FORMULATIONS FOR MODULATING MYC EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250429-A2 | COMBINATION THERAPIES COMPRISING MYC MODULATION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230399423-A1 | POLYMERIC DISINFECTANTS AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-4183770-A1 | CONTINUOUS FLOW PROCESS FOR PRODUCTION OF CATIONIC LIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-24 | — | — | EP | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2005011721-A2 | USE OF A PAK INHIBITOR FOR THE TREATMENT OF A JOINT DISEASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
| US-20050014870-A1 | Resin composition | SONY CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1498133-A1 | Use of a pak inhibitor for the treatment of a joint disease | Aventis Pharma Deutschland GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| US-6794530-B1 | 1,4-ADDITION OF MONOHYDRIC OR POLYHYDRIC ALCOHOLS TO ALPHA , BETA -UNSATURATED NITRILES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-0934925-B1 | Process for the preparation of beta-alkoxy nitriles | BASF AG (DE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0934925-A1 | Process for the preparation of beta-alkoxy nitriles | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0594292-B1 | Polyols and their use for the manufacture of polyurethanes. | ICI PLC (GB) | 1998-01-21 | — | — | EP | disclosed |
| US-5710232-A | Poly(ester-amide) polyols | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-01-20 | — | — | US | disclosed |
| EP-0594292-A1 | Novel polyols | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-27 | — | — | EP | disclosed |